KP Labs and Frontgrade Gaisler Join Forces to Advance Fault-Tolerant Computing for Next-Generation Space Missions
18.11.2025 14:00:00 CET | Business Wire | Press Release
KP Labs, a European Leader in delivering autonomous systems for space applications and Frontgrade™ Gaisler Technologies, a leading provider of high-reliability electronic solutions for space and national security missions have signed a Memorandum of Understanding during the Space Tech Expo Europe in Bremen, Germany. The agreement establishes a framework for collaboration in developing and validating advanced on-board computing architectures designed to increase the autonomy and resilience of future space missions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118359687/en/
As satellite operators and mission designers increasingly rely on on-board data processing and autonomy, maintaining fault tolerance and reliability has become a critical priority. To meet these demands, modern spacecraft integrates radiation-hardened components and advanced FDIR (Fault Detection, Isolation and Recovery) systems that ensure stable operation even in the most challenging radiation environments. The collaboration between KP Labs and Frontgrade Gaisler aims to address these challenges by combining robust computing platforms with intelligent data processing systems - creating a foundation for more autonomous and resilient satellite missions.
The agreement sets the stage for joint developments combining Frontgrade Gaisler’s expertise in radiation-hardened processors and fault-tolerant SoC design with KP Labs’ experience in autonomous data processing and system-level supervision. Together, the companies will explore opportunities to enhance reliability and performance across a range of on-board processing applications – from small satellites to planetary exploration platforms.
“By collaborating with Frontgrade Gaisler, we’re joining forces with one of the most respected companies in fault-tolerant space computing,” said Michał Zachara, COO at KP Labs. “Our goal is to merge proven reliability with advanced autonomy – enabling smarter, more resilient missions that can operate with greater independence from the ground.”
“Our products aim to enable modern on-board data processing architecture, enhancing integration and efficiency,” said Sandi Habinc, General Manager at Frontgrade Gaisler. “Collaborating with KP Labs’ team of experts will help shape the path towards scalable, intelligent spacecraft systems “
The ongoing technical cooperation between the two companies includes the integration of Frontgrade Gaisler’s GR716B microcontroller within KP Labs’ Lion Data Processing Unit (DPU) architecture. Furthermore, the Lion DPU also incorporates Frontgrade’s radiation-tolerant memory devices, including the 4Tb NAND flash.
GR716B is a rad-hard mixed-signal microcontroller, with a wide range of interfaces as well as the capabilities to control motors and power systems. Furthermore, it includes hardware functionality to program and scrub the configuration memory of Kintex Ultrascale and Virtex5 FPGAs, enabling flexibility and fault tolerance in systems such as KP Labs’s Lion DPU.
Lion is a backplane-based DPU in ADHA 3U form factor designated to satellites up to 600 kg. Designed for the ESA Mission Class III and IV, it utilizes Kintex Ultrascale FPGA to deliver enhanced resilience and processing power for critical applications.
Future joint activities will focus on validation, interoperability, and performance benchmarking, with results expected to inform upcoming mission concepts in 2026 and beyond.
About KP Labs
Founded in 2016, KP Labs is a Polish space technology company advancing space exploration through the development of autonomous mission operations and onboard data processing systems. The company offers end-to-end solutions, including integrated hardware platforms, proprietary software, and advanced AI algorithms for Earth observation and planetary missions. KP Labs is involved in 9 space missions and has delivered over 35 R&D projects for the European Space Agency (ESA), NASA, and commercial clients. With a team of around 85 engineers and researchers, the company holds the status of an official R&D Center granted by the Polish Ministry of Science and Higher Education.
About Frontgrade Gaisler
Frontgrade Gaisler, a Frontgrade company, is a leading provider of radiation-hardened microprocessors and IP cores for critical applications, particularly in the space industry. The company’s processors are ideal for any space mission or other high-reliability application due to their reliability, fault tolerance, and radiation tolerance. Frontgrade Gaisler microprocessors can be found all over the solar system, from Mercury to Neptune.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251118359687/en/
Contacts
Media Contacts
Julia Wiśniowska
Head of Marketing, KP Labs
jwisniowska@kplabs.pl
+48 530 523 011
Susanne Folkesson, Frontgrade Gaisler
Communications Manager
Susanne.folkesson@gaisler.com
+46 31 7758650
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom